PROTOCOLS, MEDICATIONS & DEVICES (PMD) STANDING COMMITTEE

Minutes

November 15, 2012 - 12:00 PM
150 N. 18th Ave., Conference Room 540A

I. Call to Order – Toni Gross, MD, Chair

Meeting was called to order at 12:01 p.m.

II. Roll Call – Jennifer Herbert (12 Members, 7 required for quorum)

<table>
<thead>
<tr>
<th>Members Present</th>
<th>Members Absent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Toni Gross, MD (Chair)</td>
<td>Rob Jarvis</td>
</tr>
<tr>
<td>Patricia Ellis, RN*</td>
<td>Terry Shine, RN</td>
</tr>
<tr>
<td>Charlie Smith (EMS Liaison)</td>
<td>Steven Curry, MD</td>
</tr>
<tr>
<td>Terry Mason (Vice Chair)</td>
<td>Michael Pfleger, MD (STAB Liaison)</td>
</tr>
<tr>
<td>Garth Gemar, MD</td>
<td>Sue Kern, RN</td>
</tr>
<tr>
<td>Jason Johnson, M.D.*</td>
<td></td>
</tr>
<tr>
<td>Bruce Toliver*</td>
<td></td>
</tr>
</tbody>
</table>

* indicates teleconference

III. Chairman’s Report – Toni Gross, MD

a. Membership update: Welcome Jason Johnson, MD

IV. Bureau Report – Ben Bobrow, MD: Dr. Bobrow had nothing to report.

V. Discussion and Action Items

a. Discuss, amend, and approve PMD minutes of May 24, 2012

Charlie Smith made a motion to approve the May 24, 2012 minutes as presented and Terence Mason seconded the motion. **Motion passes and minutes are approved.**

b. Select a workgroup to update the Triage, Treatment and Transport Guidelines

c. Select a workgroup to propose updates to R9-25-503, Table 1 (drug box)

d. Select a workgroup to propose updates to the Drug Profiles. Members decided to form just one workgroup charged with updating the TTTG, R9-25-503 Table 1, and Drug Profiles (items b, c and d). Volunteers are as follows: Patricia Ellis, Garth Gemar, Brian Smith, Charlie Smith and Jason Johnson. **Group report to be submitted back to PMD in March, 2013.**

e. Consider additional information pertaining to the request to add Cyanokit Administration (hydroxocobalamin, 5 g for intravenous infusion) as an optional agent to R9-25-503, Table 1 – Sean Culliney.

f. Discuss, amend, approve the addition of Cyanokit Administration (hydroxocobalamin, 5 g for intravenous infusion) as an optional agent to R9-25-503, Table 1 – Sean Culliney.

Terence Mason made a motion to add the Cyanokit to the R9-25-503 Table 1 as an optional drug with the caveat that they look at the indications for use and make sure that the drug profile is satisfactory to all. Charlie Smith seconded the motion. Discussion ensued. **Motion passes and is approved.** Jennifer Herbert updated the Table 1 and the drug profile.

g. Discuss, amend, approve the addition of Ketamine as an optional agent to R9-25-503, Table 1 drug box – Garth Gemar, MD
Dr. Gemar presented the committee with a draft drug profile. Discussion ensues. Dr Gemar makes a motion to add Ketamine to Table 1 as an optional drug. Discussion ensues. **This item was not approved.**

h. Discuss, amend approve Ketamine drug profile – Garth Gemar, MD. **No action was made.**

i. Consider additional information pertaining to the request to add Proparacaine Ophthalmic drops to R9-25-503, Table 1 drug box as an optional agent – Garth Gemar, MD **No addition information was presented.**

j. Discuss, amend, approve the addition of Proparacaine Ophthalmic drops as an optional agent to R9-25-503, Table 1 drug box – Garth Gemar, MD
Dr. Gemar makes a motion to table to the March 21, 2012 meeting, Charlie Smith seconds motion. Motion carries. **This item will be tabled to the next meeting on March 21, 2013.**

VI. Agenda Items for Next Meeting: Workgroup will report back to PMD on March 21, 2012

VII. Call to the Public. No response from the public.

VIII. Summary of Current Events

IX. Next Meeting: March 21, 2012, 12:00 P.M. at 150 N. 18th Avenue, Room 540A.

X. Adjournment: Meeting adjourned at 12:55 PM.

Meeting minutes approved by PMD on March 21, 2013